Abstract
Background
Hydrocodone and oxycodone are prescribed commonly to treat pain. However, differences in risk of opioid-related adverse outcomes after an initial prescription are unknown.
This study aims to determine the risk of opioid-related adverse events, defined as either chronic use or opioid overdose, following a first prescription of hydrocodone or oxycodone to opioid naïve patients.
Methods
A retrospective analysis of multiple linked public health datasets in the state of Oregon. Adult patients ages 18 and older who a) received an initial prescription for oxycodone or hydrocodone between 2015–2017 and b) had no opioid prescriptions or opioid-related hospitalizations or emergency department visits in the year preceding the prescription were followed through the end of 2018. First-year chronic opioid use was defined as ≥6 opioid prescriptions (including index) and average ≤30 days uncovered between prescriptions. Fatal or non-fatal opioid overdose was indicated from insurance claims, hospital discharge data or vital records.
Results
After index prescription, 2.8% (n = 14,458) of individuals developed chronic use and 0.3% (n = 1,480) experienced overdose. After adjustment for patient and index prescription characteristics, patients receiving oxycodone had lower odds of developing chronic use relative to patients receiving hydrocodone (adjusted odds ratio = 0.95, 95% confidence interval (CI) 0.91–1.00) but a higher risk of overdose (adjusted hazard ratio (aHR) = 1.65, 95% CI 1.45–1.87). Oxycodone monotherapy appears to greatly increase the hazard of opioid overdose (aHR 2.18, 95% CI 1.86–2.57) compared with hydrocodone with acetaminophen. Oxycodone combined with acetaminophen also shows a significant increase (aHR 1.26, 95% CI 1.06–1.50), but not to the same extent.
Conclusions
Among previously opioid-naïve patients, the risk of developing chronic use was slightly higher with hydrocodone, whereas the risk of overdose was higher after oxycodone, in combination with acetaminophen or monotherapy. With a goal of reducing overdose-related deaths, hydrocodone may be the favorable agent.
Funder
National Institute on Drug Abuse
Agency for Healthcare Research and Quality
Publisher
Public Library of Science (PLoS)
Reference40 articles.
1. IQVIA Institute. Medicine Use and Spending in the U.S. A Review of 2017 and Outlook to 2022. April 19, 2018. https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-use-and-spending-in-the-us-review-of-2017-outlook-to-2022. Accessed March 13, 2022.
2. Drug Enforcement Agency Drug and Chemical Evaluation Section. Hydrocodone. October 2019. https://www.deadiversion.usdoj.gov/drug_chem_info/hydrocodone.pdf. Accessed March 13, 2022.
3. Drug Enforcement Agency Drug and Chemical Evaluation Section. Oxycodone. March 2020. https://www.deadiversion.usdoj.gov/drug_chem_info/oxycodone/oxycodone.pdf. Accessed March 13, 2022.
4. Geographic Variation in Opioid Prescribing in the U.S;DC McDonald;The Journal of Pain,2012
5. Prescription and Prescriber Specialty Characteristics of Initial Opioid Prescriptions Associated with Chronic Use;SG Weiner;Pain Med,2020
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献